5-Lipoxygenase inhibitors: a review of recent developments and patents
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
IMPORTANCE TO THE FIELD: Leukotrienes (LTs) are pivotal lipid mediators of inflammation and allergy and results from recent studies also suggest roles of LTs in cardiovascular diseases, cancer and osteoporosis. 5-Lipoxygenase (5-LO) catalyzes the first step in the biosynthesis of LTs from arachidonic acid, and based on the multiple potent pathophysiological actions of LTs, the pharmacological intervention with 5-LO is a challenge in the development of therapeutics. AREAS COVERED IN THIS REVIEW: We first summarize the biochemical regulation of 5-LO and the general pharmacological concepts in 5-LO inhibition by currently available compounds, and subsequently we report recent developments deduced from recent scientific publications and patents. WHAT THE READER WILL GAIN: A comprehensive overview about the different molecular pharmacological strategies to inhibit 5-LO and the most successful previous 5-LO inhibitors. The review also gives insights into novel concepts, for example, dual prostaglandin/LT synthesis inhibition and reveals novel compounds patented or developed within the past 5 years. TAKE HOME MESSAGE: Despite the increasing therapeutic indications of anti-LT therapy, the progress in the development of novel 5-LO inhibitors is moderate. However, novel molecular concepts in the intervention with LT biosynthesis seem promising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932 · cited 1×
“Finally, the combined action of 5-LO and 12-LO or 15-LO can lead to lipoxins, which are bioactive trihydroxytetraene-containing lipid mediators that appear to function as stop signals for inflammatory responses and to promote repair and wound healing [5].”
BackgroundLeukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233 · cited 1×
“The LTA4 formed by 5-LO is an unstable intermediate and can be enzymatically converted to LTB4 by LTA4 hydrolase, or conjugated with glutathione to LTC4 by LTC4 synthase, depending on the cell type and the enzymes present (Figure 1) [3].”
BackgroundPeters-Golden, M., & Henderson, W. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071371 · Cited by 1,013
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke
Helgadottir, A., Manolescu, A., Thorleifsson, G., Gretarsdottir, S., Jonsdottir, H., Thorsteinsdottir, U., Samani, N. J., Gudmundsson, G., Grant, S. F. A., Thorgeirsson, G., et al. (2004) · Nature Genetics · doi:10.1038/ng1311 · Cited by 927 · cited 1×
“Recent studies with mice and humans clearly identified the 5-LO or FLAP gene as risk factors for atherosclerosis as well as for other cardiovascular diseases including stroke and myocardial infarction [23,24] and anti-LTs are now under evaluation for the treatment of cardiovascular diseases [25].”
BackgroundRole of cytosolic phospholipase A2 in allergic response and parturition
Uozumi, N., Kume, K., Nagase, T., Nakatani, N., Ishii, S., Tashiro, F., Komagata, Y., Maki, K., Ikuta, K., Ouchi, Y., et al. (1997) · Nature · doi:10.1038/37622 · Cited by 704 · cited 1×
“, by glucocorticoids) would prevent the formation of all eicosanoids, as supported by experiments in cPLA2-deficient mice [57].”
Result5-Lipoxygenase: regulation of expression and enzyme activity
Rådmark, O., Werz, O., Steinhilber, D., & Samuelsson, B. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.06.002 · Cited by 471 · cited 4×
“5-LO activity is strongly stimulated by Ca2þ, which binds to the N-terminal C2-like domain of 5-LO (for review see [27]).”
BackgroundInfluentialSelf-citationSpanbroek, R., Gräbner, R., Lötzer, K., Hildner, M., Urbach, A., Rühling, K., Moos, M. P. W., Kaiser, B., Cohnert, T. U., Wahlers, T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242716099 · Cited by 458 · cited 1×
“The levels of 5-LO correlated with the stages of atherosclerotic lesions [20] and with plaque instability [21] and LTB4 may contribute to intimal hyperplasia [22].”
BackgroundRole of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene
Chen, X.-S., Shelter, J. R., Johnson, E. N., & Funk, C. D. (1994) · Nature · doi:10.1038/372179a0 · Cited by 414 · cited 1×
“Studiesusing5-LOmice confirmeda roleof5-LOproducts in certain acute inflammatory responses including AA-induced ear inflammation and zymosan- or immune-complex-induced peritonitis, and allergic airway inflammation, as well as a crucial role in platelet-activating factor (PAF)-induced shock [17].”
BackgroundBoswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase.
Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M. I., Subramanian, L. R., & Ammon, H. P. T. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11130-0 · Cited by 400 · cited 1×
“4 Diverse 5-LO inhibitors A unique but yet undefinedmechanism of 5-LO inhibition was suggested for 3-O-acetyl-11-keto-boswellic acid (AKBA, compound 9, Figure 3), an ingredient of the gum-resin derived from Boswellia species that acts directly on 5-LO, apparently at a site that is different from the catalytic AA-bindi…”
Background
Cited by
Physiological role of taurine – from organism to organelle
Lambert, I. H., Kristensen, D. M., Holm, J. B., & Mortensen, O. H. (2015) · Acta Physiologica · doi:10.1111/apha.12365 · Cited by 360
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Cannflavins—From plant to patient: A scoping review
Erridge, S., Mangal, N., Salazar, O., Pacchetti, B., & Sodergren, M. H. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104712 · Cited by 45
Metadata
- Authors
- Pergola, C., & Werz, O.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2010-02-24
- Volume
- 20
- Issue
- 3
- Pages
- 355-375
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2102136911
- Cited by
- 183
- References
- 84
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.